ZSCAN23 is a zinc finger transcription factor with DNA-binding and RNA polymerase II-specific transcriptional regulatory activity. It functions as a tumor suppressor in pancreatic ductal adenocarcinoma (PDAC), where it is frequently silenced through promoter methylation (60.21% of cases) 1. ZSCAN23 expression inhibits cancer cell proliferation, colony formation, migration, and invasion while inducing apoptosis and G1/S cell cycle arrest 1. Mechanistically, it suppresses Wnt signaling by interacting with myosin heavy chain 9 (MYH9) 1, and suppresses PDAC xenograft growth in vivo 1. ZSCAN23 also shows clinical significance for human longevity, with common variants at the ZSCAN23 locus associated with lifespan in UK Biobank analyses 23. Additionally, ZSCAN23 was identified as a pleiotropic gene shared between epilepsy and psychiatric disorders, particularly implicated in MAPK signaling pathways 4. The gene has also been detected as a somatic mutation in thyrotropin-secreting pituitary adenomas, though with unknown functional role in this context 5. ZSCAN23 represents a potential biomarker for PDAC diagnosis and a therapeutic target for cancer suppression.